Molecular subtyping of advanced bladder cancer patients and patient-derived organoids based on a 3-marker immunohistochemistry approach to evaluate chemotherapy sensitivity
Our findings suggest that our 3-marker classification system could be valuable as method in future BC patient subtyping for clinical stratification of patients undergoing cisplatin-based treatment.
Authors
- Bastiaan J. Viergever (ORCID: https://orcid.org/0000-0001-7281-5872)
- Susanne J. van Schelven
- Onno Kranenburg (ORCID: https://orcid.org/0000-0002-2112-4390)
- Richard P. Meijer (ORCID: https://orcid.org/0000-0003-2510-7982)
- Eric Kalkhoven (ORCID: https://orcid.org/0000-0002-9713-7286)
- Denise Westland
- Alba C Zuidema
- Trudy G. N. Jonges (ORCID: https://orcid.org/0009-0006-9499-5310)
Institutions
- Utrecht University (NL)
- University Medical Center Utrecht (NL)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1016/j.urolonc.2025.09.023
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00